Atomic AI combines artificial intelligence analysis with wet lab experiments to discover small molecules capable of drugging RNA. The startup, based on technology initially developed at Stanford, is backed by a $35 million Series A round of financing.
Merck aims to bolster its genetic medicines pipeline through a new research alliance with Orna Therapeutics, a startup whose technology forms RNA into a circle shape that brings several advantages for new therapies and vaccines. In addition to starting the partnership, the pharmaceutical giant also invested in Orna’s $221 million Series B financing round.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.
Recognized as Method of the Year by Nature in 2020, spatial transcriptomics employs advanced imaging methods with novel chemistry techniques that stand to dramatically expand our understanding of health and disease.
CAMP4 Therapeutics is developing a new kind of RNA therapy that treats disease by upregulating gene expression. The startup has raised $45 million as CEO Josh Mandel-Brehm steers toward clinical trials expected to begin next year in liver and brain diseases.
Auris Medical has acquired Trasir Therapeutics, a startup developing technology that expands the delivery of RNA medicines to tissues beyond the liver. Going forward, Auris will sell or spin off its programs in hearing disorders and allergies and focus exclusively on RNA therapies.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Incubated by Flagship Pioneering, biotech firm Laronde is developing endless RNA, or eRNA, a new class of medicines that goes beyond messenger RNA-based therapies. Flagship is backing the startup $50 million in Series A financing.
By harnessing the combined power of NGS, machine learning and the dynamic nature of RNA we’re able to accurately measure the dynamic immune response and capture a more comprehensive picture of what’s happening at the site of the solid tumor.
The deal will involve using Arrakis' RNA-targeted small molecule platform technology to discover potential drugs in the research and development areas on which the Swiss drugmaker focuses.
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
“To our knowledge, we’re going to be the first blood-based RNA test for multiple sclerosis and definitely among the first – if not the first – in the field of autoimmune diseases,” said IQuity CEO Chase Spurlock.
Boston-based Arrakis has officially launched with a $38 million Series A and a unique mission to bind RNA with small molecules.
“We showed that cancer stem cells co-opt an RNA editing system to clone themselves. What’s more, we found a method to dial it down,” said principal investigator Dr. Catriona Jamieson, of UC San Diego School of Medicine.
Its core science comes from Harvard Stem Cell Institute researcher Richard Gregory, who focuses on the function of miRNA in disease manifestation. We're guessing Homology Medicines is in this field as well.
Advanced Cell Diagnostics just raised a $22 million Series C to enter the clinical and research diagnostics space - with aims to be used as a precision medicine tool. It profiles single gene expression in situ, studying the targeted molecular structure of each cell in a sample - and can detect every gene in the human transcriptome, the startup says.